Dataset Information

Antilipidemic Drug Therapy Today and in the Future.

ABSTRACT: The armamentarium for the treatment of dyslipidemia today comprises six different modes of action with overall around 24 different drugs. The treatment of lipid disorders was revolutionized with the introduction of statins which have become the most important therapeutic option available today to reduce and prevent atherosclerosis and its detrimental consequences like cardiovascular diseases and stroke. With and optimized reduction of elevated LDL levels with statins, the risk for cardiovascular diseases (CVD) can be reduced by 30%, indicating a residual remaining risk of 70% for the development and progression of CVD notifying still a high medical need for more effective antilipidemic drugs. Consequently, the search for novel lipid-modifying drugs is still one of the most active areas in research and development in the pharmaceutical industry. Major focus lies on approaches to LDL-lowering drugs superior to statins with regard to efficacy, safety, and patient compliance and on approaches modifying plasma levels and functionality of HDL particles based on the clinically validated inverse relationship between high-plasma HDL levels and the risk for CVD. The available drugs today for the treatment of dyslipidemia are small organic molecules or nonabsorbable polymers for binding of bile acids to be applied orally. Besides small molecules for novel targets, biological drugs such as monoclonal antibodies, antisense or gene-silencing oligonucleotides, peptidomimetics, reconstituted synthetic HDL particles and therapeutic proteins are novel approaches in clinical development are which have to be applied by injection or infusion. The promising clinical results of several novel drug candidates, particularly for LDL cholesterol lowering with monoclonal antibodies raised against PCSK9, may indicate more than a decade after the statins, the entrance of new breakthrough therapies to treat lipid disorders.

SUBMITTER: Kramer W

PROVIDER: S-EPMC7122375 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Antilipidemic Drug Therapy Today and in the Future.

Kramer Werner W

Handbook of experimental pharmacology 20160101

The armamentarium for the treatment of dyslipidemia today comprises six different modes of action with overall around 24 different drugs. The treatment of lipid disorders was revolutionized with the introduction of statins which have become the most important therapeutic option available today to reduce and prevent atherosclerosis and its detrimental consequences like cardiovascular diseases and stroke. With and optimized reduction of elevated LDL levels with statins, the risk for cardiovascular ...[more]

PMID: 26330256

Similar Datasets

Project description:In the present article, we explore prospects for using artificial intelligence (AI) to distribute cognition via cognitive offloading (i.e., to delegate thinking tasks to AI-technologies). Modern technologies for cognitive support are rapidly developing and increasingly popular. Today, many individuals heavily rely on their smartphones or other technical gadgets to support their daily life but also their learning and work. For instance, smartphones are used to track and analyze changes in the environment, and to store and continually update relevant information. Thus, individuals can offload (i.e., externalize) information to their smartphones and refresh their knowledge by accessing it. This implies that using modern technologies such as AI empowers users via offloading and enables them to function as always-updated knowledge professionals, so that they can deploy their insights strategically instead of relying on outdated and memorized facts. This AI-supported offloading of cognitive processes also saves individuals' internal cognitive resources by distributing the task demands into their environment. In this article, we provide (1) an overview of empirical findings on cognitive offloading and (2) an outlook on how individuals' offloading behavior might change in an AI-enhanced future. More specifically, we first discuss determinants of offloading such as the design of technical tools and links to metacognition. Furthermore, we discuss benefits and risks of cognitive offloading. While offloading improves immediate task performance, it might also be a threat for users' cognitive abilities. Following this, we provide a perspective on whether individuals will make heavier use of AI-technologies for offloading in the future and how this might affect their cognition. On one hand, individuals might heavily rely on easily accessible AI-technologies which in return might diminish their internal cognition/learning. On the other hand, individuals might aim at enhancing their cognition so that they can keep up with AI-technologies and will not be replaced by them. Finally, we present own data and findings from the literature on the assumption that individuals' personality is a predictor of trust in AI. Trust in modern AI-technologies might be a strong determinant for wider appropriation and dependence on these technologies to distribute cognition and should thus be considered in an AI-enhanced future.

Project description:Interventions: Future Health Today (FHT) trial is testing a quality improvement (QI) program in order to reduce cardiovascular disease (CVD) risk in people with chronic kidney disease (CKD) and to facilitate earlier diagnosis of cancer in general practice. The intervention consists of: 1.Technology platform consisting of audit, point of care clinical decision support, and QI templates. Practices will generate a baseline cohort of patients using the audit tool at the beginning of the trial. The progress of the cohort will be automatically updated using the Future Health Today platform over the trial duration. Practices will be encouraged to review their progress and complete a minimum of three reviews of audit data as part of an accredited Royal Australian College of General Practitioners (RACGP) quality improvement activity. These can be carried out at any time during the trial, but we will recommend that they are conducted at least once every four months over the 12-month trial period. The point of care tool will automatically deploy when the electronic medical record of an eligible patient is opened and will provide a prompt regarding guideline-concordant care. The QI template has been developed specifically for this study, and aligns to RACGP requirements. 2.ECHO (Extension for Community Healthcare Outcomes) education activities. ECHO sessions are delivered using the zoom videoconference platform. The 60-minute sessions consist of (1) Introductions of participants (2) Delivery of a short didactic lecture (approximately 10 minutes in duration), followed by question and answer session (3) Presentation of a clinical case by a participant followed by feedback from participants and an expert panel. Each arm will receive 3 ECHO sessions based on their allocation (see below). T Primary outcome(s): Proportion of eligible patients with CKD (coded diagnosis or pathology consistent with diagnosis of CKD) that are receiving ACE inhibitors or Angiotensin receptor blockers and/or statins consistent with Kidney Health Australia, RACGP Red Book and National Vascular Disease Prevention Alliance Guidelines.[ 12 months post-baseline];Proportion of eligible patients at risk of undiagnosed prostate, oesophageal, gastric, colorectal, endometrial, lung or ovarian cancer that have been assessed and investigated according to NICE, Cancer Council Australia, Victorian Government Department of Health and Human Services, Prostate Cancer Foundation of Australia guidelines. This will be assessed utilising data extracted from electronic medical records and stored in the Department of General Practice, University of Melbourne Patron dataset. [ 12 months post-baseline] Study Design: Purpose: Educational / counselling / training; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;Type of endpoint: Efficacy

Dataset Information

Antilipidemic Drug Therapy Today and in the Future.

Publications

Antilipidemic Drug Therapy Today and in the Future.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure